Under the terms of the agreement, Artech placed an initial stocking order for E90,000 (approximately $144,000) for RenalGuard Consoles and single use sets to support the initial sales launch of RenalGuard at selected major cardiology centers throughout Italy.
Artech will target early adopters who recognize the benefits of utilizing the unique fluid balancing capabilities of RenalGuard System in a cath lab setting during cardiovascular imaging procedures for patients at higher risk of contrast-induced nephropathy.
Emilio Contini, Artech’s president, said: “RenalGuard offers Artech the opportunity to represent an innovative new therapy that can potentially improve the outcomes in interventional procedures requiring contrast for high risk patients.”